glp 1 perimenopause weight gain GLP-1s, Obesity, and Menopause: Benefits and Risks MENOPAUSAL WEIGHT GAIN AND GLP1

Europe Patent Number EP 2120994, 2018

The mechanism is progressive: GH-mediated lipolysis depletes triglyceride stores in visceral adipocytes over time, but the rate slows as adipocyte volume decreases and HSL expression normalizes

General Well-being: Designed to support overall well-being

Many medications can lead to urinary retention and something we call overflow incontinence, which is when the bladder is not able to contract and expel urine effectively, leaving urine in the bladder, says Brooke D

Diagnosis and clinical management of obesity cardiomyopathy remain challenging due to its similarity to dilated cardiomyopathy and the difficulty in isolating the effects of obesity from comorbidities [21]

Glucose abnormalities are well established risk factors for coronary artery disease (CAD)2, and they are considerably more common in patients with acute and chronic coronary syndromes (ACS, CCS) than in the general population